BridgeBio Pharma Announces Positive Data From Phase 1/2 Study Of Encaleret In Autosomal Dominant Hypocalcemia Type 1 (ADH1)

Monday, June 3, 2024 1 min read

Key Takeaway: BridgeBio Pharma Announces Positive Data From Phase 1/2 Study Of Encaleret In Autosomal Dominant Hypocalcemia Type 1 (ADH1)

Full Press Release Details

BridgeBio Pharma Announces Positive Data From Phase 1/2 Study Of Encaleret In Autosomal Dominant Hypocalcemia Type 1 (ADH1).